Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cybin Inc. stock logo
CYBN
Cybin
$8.34
+11.6%
$6.70
$4.81
$13.88
$160.43M0.6253,841 shs558,772 shs
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
$6.87
-1.4%
$11.40
$6.15
$1,838.76
$5.72M1.52100,145 shs41,015 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.93
+2.1%
$1.39
$0.77
$2.12
$192.57M2.341.50 million shs4.28 million shs
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
$0.89
-3.0%
$8.88
$0.15
$9.75
$37.71M3.5121.62 million shs822,036 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cybin Inc. stock logo
CYBN
Cybin
+11.65%+18.97%+19.31%+0.97%+2,160.16%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-1.43%-2.00%-35.43%-92.68%-99.99%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
+2.12%-0.52%+37.86%+67.83%+37.86%
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
0.00%-4.49%-17.33%-20.21%-26.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cybin Inc. stock logo
CYBN
Cybin
2.5711 of 5 stars
3.60.00.00.03.20.81.3
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
2.5317 of 5 stars
3.52.00.00.04.20.01.3
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.4046 of 5 stars
0.02.00.00.03.50.00.6
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$86.00931.18% Upside
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.003,975.69% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VTL, SLS, CYBN, and RNAZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/16/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
3/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
3/13/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$560.00 ➝ $560.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A$86.32 per shareN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M192.57N/AN/A($0.25) per share-7.72
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
N/AN/AN/AN/A$0.29 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
-$41.47MN/A0.00N/AN/A-235.33%-182.35%N/A

Latest VTL, SLS, CYBN, and RNAZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
3/20/2025Q4 2024
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.08+$0.0267-$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
1.58
1.58
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
2.26
2.26
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
N/A
6.97
6.97

Institutional Ownership

CompanyInstitutional Ownership
Cybin Inc. stock logo
CYBN
Cybin
17.94%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
15.52%

Insider Ownership

CompanyInsider Ownership
Cybin Inc. stock logo
CYBN
Cybin
15.00%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
33.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cybin Inc. stock logo
CYBN
Cybin
5021.48 million17.96 millionNot Optionable
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
9833,000677,000Not Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million69.54 millionNot Optionable
Vital Therapies, Inc. stock logo
VTL
Vital Therapies
1042.37 millionN/ANot Optionable

Recent News About These Companies

Lighthouse Center for Vital Living celebrates new building
Alternative Wellness Therapies in the Tahoe Basin
Ending Therapy
Medication and Therapy
Vardhman Textiles Ltd.
Don’t Forget About Vital Signs in Psychiatry Visits
Teen Therapy and Psychiatry Online: Hit or Miss?
Vital Ltd VTL

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cybin stock logo

Cybin NYSE:CYBN

$8.34 +0.87 (+11.65%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$8.30 -0.04 (-0.42%)
As of 08:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$6.87 -0.10 (-1.43%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.17 +0.30 (+4.37%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.93 +0.04 (+2.12%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.07 (+3.37%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Vital Therapies stock logo

Vital Therapies NASDAQ:VTL

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.